Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327533 | 0.93 | HSP90AA1 (0.65) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL25886876 | 0.86 | HSP90AA1 (0.51) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL28092025 | 0.83 | CHRNB4 (0.67) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL27751200 | 0.83 | ALDH1A1 (0.45) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL10452140 | 0.82 | ALDH1A1 (0.47) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL19204937 | 0.80 | HSP90AA1 (0.57) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL12825154 | 0.80 | HSP90AA1 (0.57) | HSP90AA1ALDH1A1CHRNB4CHRNA3NOS3 | |
| SCHEMBL5739346 | 0.79 | HSP90AA1 (0.49) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL27892542 | 0.79 | HSP90AA1 (0.55) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 | |
| SCHEMBL1531296 | 0.79 | HSP90AA1 (0.84) | HSP90AA1ALDH1A1HIF1ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| CN-113302196-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220064196-A1 | EGFR Inhibitors, Compositions and Methods Thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-03-03 | — | — | US | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| CN-113302196-A | EGFR inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020147702-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064196-A1 | EGFR Inhibitors, Compositions and Methods Thereof | EGFR, ERBB2, ERBB3 | HSP90AA1 1625/4885ALDH1A1 3755/4885HIF1A 680/4885 |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | HSP90AA1 1046/4885ALDH1A1 2707/4885HIF1A 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.